SVRA – savara, inc. (US:NASDAQ)

News

Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara: A High-Risk Opportunity [Seeking Alpha]
Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com